Brain Activity, Cognitive Function, and Walking Ability in Parkinson's Disease

March 20, 2026 updated by: Yea-Ru Yang, National Yang Ming Chiao Tung University

Brain Activity, Cognitive Function, and Walking Ability in People With Parkinson's Disease

The dual-task automated walking performance in people with Parkinson's disease (PD) is affected by their gait disturbances and impaired executive functions. Currently, the relationship between brain activity related to inhibitory control, executive functions, and dual-task walking performance in people with PD is not well understood. Therefore, this study aims to investigate the significance of different executive function domains on gait stability in healthy older adults and people with PD; whether brain activation related to inhibitory control is associated with gait stability in healthy older adults and people with PD.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Taiwan
      • Taipei, Taiwan
        • Recruiting
        • National Yang Ming Chiao Tung University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Hospital and community

Description

Inclusion Criteria:

  • Diagnoses of idiopathic Parkinson disease
  • Stable dopaminergic medicine ≥ 2 weeks
  • Able to walk 10 meters without aid
  • Mini-Mental Status Examination ≥ 24 points
  • No uncorrected visual or auditory disorders
  • Education at least junior high school
  • No other disease may affect balance

Exclusion Criteria:

  • Other medical diagnoses of neurological, musculoskeletal, or cardiopulmonary disorders
  • History of brain surgery (e.g. deep brain stimulation)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Parkinson disease
People with Parkinson disease
Behavioral: Cognitive function, gait, and electroencephalogram
Measurement of cognitive function, gait performance, and electroencephalogram
Healthy older adults
Behavioral: Cognitive function, gait, and electroencephalogram
Measurement of cognitive function, gait performance, and electroencephalogram

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gait variability
Time Frame: 1 day
Using GAITRite system to measure the coefficient of variation (CV). The mean and standard deviation will be used to calculate the coefficient of variation (CV). CV = standard deviation / mean * 100%
1 day
Gait speed
Time Frame: 1 day
Using GAITRite system to measure gait speed.
1 day
Step length
Time Frame: 1 day
Using GAITRite system to measure step length
1 day
Step width
Time Frame: 1 day
Using GAITRite system to measure step width.
1 day
Single support time
Time Frame: 1 day
Using GAITRite system to measure single support time
1 day
Double support time
Time Frame: 1 day
Using GAITRite system to measure double support time
1 day
Frontal Assessment Battery
Time Frame: 1 day
The score ranged from 0 to 18. Higher scores show better executive function.
1 day
Trail making test
Time Frame: 1 day
Trail making test contain part A and part B. Faster completing the test indicates better executive function.
1 day
Stroop color and word test
Time Frame: 1 day
Record numbers of corrected color words which the subject responds within 45 sec.
1 day
Digit span test
Time Frame: 1 day
Digit span test contain forward and backward part. Scores of forward digit span ranges from 0 to 16. Score of backward digit span ranges from 0 to 14. Higher scores indicate better executive function.
1 day
Event-related potential - N2
Time Frame: 1 day
Measure event-related potential through electroencephalography under single-task and dual-task paradigm.
1 day
Event-related potential - P300
Time Frame: 1 day
Measure event-related potential through electroencephalography under single-task and dual-task paradigm.
1 day
Go/Nogo test
Time Frame: 1 day
Behavioral test during measuring electroencephalography.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Yang Ming Chiao Tung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 9, 2024

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 31, 2027

Study Registration Dates

First Submitted

September 5, 2024

First Submitted That Met QC Criteria

September 5, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 24, 2026

Last Update Submitted That Met QC Criteria

March 20, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NYCU113006AF1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe